Company News
Sumitomo Pharma Accused of ¥165bn Revenue Misstatement
Gotham City Research alleges Sumitomo Pharma misstated FY2025 revenue by up to ¥165 billion ($1.05 bn).
The claim centers on a ¥48 billion dividend from Swiss subsidiary SMPS reported as a ¥164 billio
